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Background: Binding of HIV to the chemokine coreceptor CXCR4 mediates viral fusion and signal transduction that
promotes actin dynamics critical for HIV infection of blood resting CD4 T cells. It has been suggested that this
gp120-mediated actin activity resembles the chemotactic actin dynamics mediated by chemokines such as SDF-1.
To determine whether inhibiting SDF-1-mediated chemotactic activity can also inhibit HIV infection, we screened
several inhibitors known to reduce SDF-1-mediated chemotaxis of T cells.
Results: We found that a tyrosine kinase inhibitor, genistein, inhibited both SDF-1-mediated chemotaxis and HIV
infection of resting CD4 T cells. Genistein was also found to interfere with SDF-1- and HIV-mediated actin dynamics
in CD4 T cells. This reduction in actin activity correlates with genistein-mediated inhibition of viral DNA
accumulation in resting CD4 T cells. In addition, we also tested two other tyrosine kinase inhibitors, sunitinib and
AG1478. Sunitinib, but not AG1478, inhibited HIV infection of resting CD4 T cells. We further tested the safety of
genistein in 3 Chinese rhesus macaques (Macaca mulatta), and each animal was given a monotherapy of genistein
at 10 mg/kg orally for 12 weeks. No adverse drug effects were observed in these animals.
Conclusions: Our results suggest that novel therapeutic strategies can be developed based on targeting cellular
proteins involved in HIV-dependent signaling. This approach can interfere with HIV-mediated actin dynamics and
inhibit HIV infection.
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Binding of HIV to CD4 and the chemokine coreceptor
CXCR4 or CCR5 mediates viral fusion and entry [1-8].
This interaction also triggers the activation of signaling
molecules [9-11]. In particular, HIV binding to CXCR4 ac-
tivates actin regulators such as LIMK1 and cofilin, pro-
moting actin dynamics necessary for viral infection of
resting T cells [12-16]. In vivo, chemokine receptor signal-
ing promotes actin dynamics for chemotactic cell migra-
tion. Consistently, induction of actin activity by treatment
of resting CD4 T cells with chemokines such as CCL2
augments gp120-induced F-actin polymerization and* Correspondence: ywu8@gmu.edu
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reproduction in any medium, provided the orenhances viral DNA synthesis [17]. Similar treatment of
memory CD4 T cells with CCL19 triggers cofilin activation
and changes in actin filaments, which greatly promote viral
nuclear localization and DNA integration [18-20]. In
addition, spinoculation of CD4 T cells triggers both cofilin
activation and actin dynamics, leading to a great enhance-
ment of HIV DNA synthesis and nuclear migration [21].
Mechanistically, HIV-mediated actin dynamics are in-
volved in viral early steps, such as entry, post-entry
DNA synthesis, and nuclear migration. During viral
entry, HIV-1 binding to resting CD4 T cells triggers a
rapid and transient actin polymerization through Rac1-
PAK1/2-LIMK1-cofilin activation [14]. This rapid actin
polymerization transiently blocks CXCR4 internalization
to prolong gp120-CXCR4 interaction for membrane fu-
sion to occur [14]. Other actin binding proteins such as. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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polymerization and anchor F-actin to membrane pro-
teins to facilitate receptor clustering and viral fusion
[22-26]. Following viral entry, the viral reverse transcrip-
tion complex may be anchored onto F-actin [27-34] for
optimal reverse transcription [12,14,35]. In addition,
HIV-mediated actin treadmilling through CXCR4 signal-
ing and cofilin activity promotes HIV intracellular mi-
gration and nuclear localization [12].
To some extent, HIV-mediated signal transduction
through CXCR4 resembles the chemotactic response
mediated by chemokines such as SDF-1, the natural lig-
and for CXCR4 [36,37]. The major biological response
of SDF-1/CXCR4 interaction is to trigger rapid actin ac-
tivity, which drives directional cell migration. Given that
both SDF-1 and HIV require actin dynamics for cell mi-
gration and infection, respectively, we speculated that in-
hibition of certain shared chemotactic pathways between
SDF-1 and gp120 may also inhibit HIV infection of rest-
ing T cells. Thus, we tested multiple known chemotactic
inhibitors of SDF-1 to determine whether these inhib-
itors can also inhibit HIV. We demonstrate that a
tyrosine kinase inhibitor, genistein, known to inhibit
SDF-1-mediated chemotaxis, inhibited HIV infection
of resting T cells.
Genistein is a tyrosine kinase inhibitor found in a number
of plants such as soybeans and flemingia vestita [38], and is
being tested for treatment of cancers such as leukemia
[39,40] and prostate cancer [41,42]. Genistein has been
shown to inhibit human prostate cancer cell migration
through inhibiting pro-motility signaling [43,44]. Genistein
similarly inhibits SDF-1-mediated chemotaxis of CD4 Tcells
[45], and is suggested to modulate the cellular distribution
of actin-binding proteins in human stromal cells by inducing
the peri-nuclear accumulation of the actin-binding proteins
formin-2 and profilin [46]. In addition, genistein has been
shown to inhibit HIV infection of resting CD4 T cells
[47,48] and macrophages by affecting an unknown early step
at entry and post-entry [49]. These previous findings have
led us to speculate that genistein may inhibit HIV infection
of resting CD4 T cells through interference with HIV-
mediated actin dynamics. In this report we demonstrate that
genistein interferes with HIV-mediated actin dynamics and
inhibits viral post-entry DNA synthesis and, to a lesser ex-
tent, viral DNA nuclear migration in resting T cells. Our re-
sults highlight the possibility that novel therapeutic
strategies can be developed to target the HIV-mediated cel-
lular signal transduction to actin dynamics.
Results
Genistein inhibits SDF-1-mediated chemotaxis and HIV
infection of resting CD4 T cells
Given that both SDF-1 and HIV trigger rapid actin re-
arrangement in resting CD4 T cells [12,50], we askedwhether chemotaxis inhibitors can also inhibit gp120-
mediated chemotactic signaling and HIV infection of
resting T cells. Indeed, the Gαi inhibitor pertussis toxin
(PTX) has been shown to inhibit both SDF-1 and gp120-
mediated actin dynamics, and HIV-1 infection of resting
T cells [12]. Thus, we tested several known SDF-1 inhib-
itors including the tyrosine kinase inhibitors herbimycin
and genistein, and the cyclic nucleotides 8-Br-cAMP and
8-Br-cGMP. These inhibitors have been previously
shown to affect SDF-1-mediated memory CD4 T cell
movement towards or away from SDF-1 [45].
We purified human resting CD45RO+/CD45RA- mem-
ory CD4 T cells by negative selection (98% pure, mea-
sured by flow cytometry, data not shown) [51], and then
similarly stimulated these cells with either SDF-1 or
HIV-1NL4-3 for a time course. We measured SDF-1- and
HIV-mediated actin dynamics, and observed quick actin
polymerization both in SDF-1- and HIV-stimulated
memory CD4 T cells, starting at 1 minute post treatment
(Figure 1A and B). Next, we treated resting memory
CD4 T cells with chemotactic inhibitors, including per-
tussis toxin (PTX), genistein, herbimycin, 8-Br-cAMP, or
8-Br-cGMP, and tested the inhibition of SDF-1-mediated
chemotaxis in a chemotactic trans-well assay (Figure 1C).
We observed reduction of memory T cell migration with
PTX and genistein, consistent with previous results [45].
However, we did not observe significant inhibition of T
cell chemotaxis in the trans-well assay by herbimycin,
8-Br-cAMP, or 8-Br-cGMP in this particular donor.
We also performed a genistein dosage-dependent assay
of SDF-1-mediated chemotaxis, and observed dosage-
dependent inhibition in concentrations from 2.5 to 10
μM (Figure 1D). However, at higher concentrations (20
and 40 μM), less inhibition was observed in this donor.
Although genistein inhibited chemotaxis at all dosages,
the overall relationship between inhibition and drug
concentration was not linear. Given that genistein likely
targets multiple tyrosine kinases which may antagonize
each other, the result was not totally surprising, and may
result from differing sensitivities of tyrosine kinases to
genistein inhibition.
To determine whether these inhibitors can also inhibit
HIV infection of resting CD4 T cells, we pretreated rest-
ing CD4 T cells with genistein, herbimycin, 8-Br-cAMP
or 8-Br-cGMP, and then infected cells with HIV-1. Fol-
lowing infection for 2 hours, cell-free virus and the in-
hibitors were washed away, and cells were incubated in
the absence of the inhibitors for 5 days, during which
productive viral replication does not occur. However,
viral replication is inducible upon CD3/CD28 stimula-
tion [52]. As shown in Figure 1E, we activated infected
cells with anti-CD3/CD28 beads and observed minimal
inhibition of HIV replication by herbimycin, 8-Br-cAMP
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Figure 1 Genistein inhibits SDF-1-mediated chemotaxis and HIV infection of resting CD4 T cells. (A) Resting memory CD4 T cells were
stimulated with SDF-1 (12.5 nM) for various times, stained with FITC-phalloidin, and then analyzed with flow cytometer. (B) Resting memory CD4
T cells were stimulated with HIV-1NL4-3 for various times and similarly stained with FITC-phalloidin and analyzed. (C) Resting memory CD4 T ells
were pretreated with pertussis toxin (PTX, 100 ng/ml), genistein (3.7 μM), herbimycin (1 μM), 8-Br-cAMP (100 μM), 8-Br-cGMP (100 μM), or DMSO
(1%, control) for 15–60 minutes, and then assayed for migration towards SDF-1 (12.5 nM). Results are expressed as the relative percentage of
migrating cells. (D) Dosage-dependent inhibition of SDF-1-mediated chemotaxis by genistein. Experiments were carried out as described in (C)
with memory T cells pretreated with different dosages of genistein. (E) Resting CD4 T cells were similarly pretreated with genistein, herbimycin,
8-Br-cAMP, 8-Br-cGMP, or DMSO, and infected with HIV-1NL4-3 for 2 hours in the continuous presence of these inhibitors. Following infection, cells
were washed twice and then cultured in the absence of the inhibitors for 5 days. Cells were activated at day 5 with anti-CD3/CD28 magnetic
beads (4 beads per cell), and viral replication was measured by p24 release. (F) Dosage-dependent inhibition of HIV-1 infection by genistein.
Experiments were carried out as described in (E) with resting T cells pretreated with different dosages of genistein. (G) Effects of genistein on T
cell activation. Resting CD4 T cells were treated with genistein at different dosages for 3 hours, washed twice, and then cultured in the absence
of genistein as described in (E). Cells were similarly activated with anti-CD3/CD28 beads. At 24 hours after stimulation, cells were stained with
PE-labeled monoclonal antibody against human CD25 or CD69, and then analyzed with flow cytometry.
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10) in this particular donor. We also performed an ex-
periment on HIV-1 infection at different genistein dos-
ages, and observed dosage-dependent inhibition inconcentrations below 5 μM (Figure 1F). However, at
higher dosages (10 and 40 μM), the inhibition were less
in this donor, similar to the chemotaxis inhibition results
in Figure 1D; although genistein inhibited HIV-1
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hibition was not strictly dosage-dependent. The inhib-
ition of HIV infection did not result from cytotoxicity or
inhibition of T cell activation by genistein; when resting
CD4 T cells were similarly treated with genistein and ac-
tivated with CD3/CD28 beads, we did not observe inhib-
ition of T cells activation at all the dosages tested, as
judged by the upregulation of the CD25 and CD69 sur-
face receptors (Figure 1G).
Genistein inhibits HIV infection of resting CD4 T cells,
viral DNA synthesis, and viral nuclear migration
To further confirm that genistein inhibits HIV infection
of resting CD4 T cells, we repeated the above experi-
ment (Figure 1E) in another 4 donors and observed in-
hibition of HIV infection by transient treatment of
resting CD4 T cells with genistein during infection
(Figure 2A and Additional file 1: Figure S1). Neverthe-
less, there were clear donor-dependent variations in the
degree of inhibition (Figure 2A). We also performed ge-
nistein pre-treatment plus one-dose post-infection treat-
ment of resting CD4 T cells, and observed complete
inhibition of HIV at all concentrations tested (2.5 to
40 μM) in one donor. In a second donor, we also ob-
served complete inhibition of HIV-1 at concentrations
from 10 to 40 μM, and partial inhibition at 2.5 and 5 μM
(Figure 2B and Additional file 1: Figure S2).
We further tested the effect of genistein on HIV infec-
tion of peripheral blood monocyte-derived macrophages.
Cells were pretreated with 37 μM (or 10 μg/ml [49]) ge-
nistein for 1 hour and infected with a primary M-tropic
HIV stain, THRO.c/2626 [53], for 2 hours. Following in-
fection, both genistein and HIV were washed away, and
viral replication was monitored. We observed inhibition
of HIV by genistein (Figure 2C), similar to a previous
report [49].
We also asked whether other clinical tyrosine kinase
inhibitors would be able to inhibit HIV infection of rest-
ing T cells, and tested two anti-tumor drugs, sunitinib
and AG1478 (tyrphostin). Sunitinib inhibits cellular sig-
naling by targeting multiple receptor tyrosine kinases
[54], whereas AG1478 selectively inhibits epidermal
growth factor receptor (EGFR) activation by inhibiting
EGFR tyrosine kinase [55]. As shown in Figure 2D, we
observed inhibition of HIV-1 infection by sunitinib at
0.2-20 μM in one donor and at 20 μM in a second
donor. We observed no inhibition of HIV-1 by AG1478
at all dosages tested (0.2-20 μM) in one donor.
Previously, Stantchev et al. reported that 5–10 μg/ml
(or 18.5-37 μM) genistein inhibited HIV infection of pri-
mary human macrophages [49]; genistein was also found
to be non-toxic to cells for these several hours of short
treatment at these dosages, and genistein also did not
affect the surface expression of CD4 and CCR5 [49].Interestingly, genistein blocked viral infection of macro-
phages if added to cells either before, at the time of in-
fection, or immediately after infection, but not 24 hours
later, suggesting that genistein-mediated inhibition is at
the step of entry and early post-entry [49]. Thus, we also
examined the early steps of HIV infection of resting
memory CD4 T cells in the presence or absence of ge-
nistein. As shown in Figure 3A, we did not observe in-
hibition of viral entry using a Nef-luciferase based entry
assay [56]. We then followed a time course of viral DNA
synthesis. HIV reverse transcription in resting CD4 T
cells is a biphasic slow process, with an early and a late
DNA synthesis phase that peaks at 2–4 hours and 1–2
days respectively [12,57]. The process of viral DNA syn-
thesis is also accompanied by viral DNA decay in the ab-
sence of chemotactic signaling to promote the nuclear
entry of newly synthesized viral DNA [12,19,58]. As
shown in Figure 3B, we observed that viral DNA synthe-
sis peaked at day 1, and then decreased by day 3; in
genistein-treated cells, viral DNA synthesis at day 1 was
greatly inhibited. We also examined early viral nuclear
entry (4 hours) which is promoted by HIV-1 gp120-
CXCR4 signaling [12]. We observed a slight early de-
crease of viral nuclear DNA in genistein-treated cells
(Figure 3D). In conclusion, our results suggest that ge-
nistein mainly inhibits the slow accumulation of viral
DNA in resting CD4 T cells, and, to a lesser extent, viral
nuclear migration. Our results are consistent with previ-
ous results on HIV infection of macrophages, suggesting
that genistein affects early post-entry steps [49]. Al-
though this previous study suggested that genistein may
also inhibit viral entry in macrophages [49], we did not
observe inhibition of viral entry in resting memory CD4
T cells using the Nef-luciferease entry assay (Figure 3A).
The difference likely resulted from possible different
modes of viral entry in these two different primary cell
types. It has been shown that HIV can enter macrophages
through membrane fusion and a macropinocytosis-like
pathway [59], whereas in blood resting CD4 T cells, the
endocytic entry pathway appears to be defective [13,60].
Genistein may have a different impact on viral entry into
these two different cell types.
Genistein interferes with SDF-1- and HIV-mediated actin
dynamics in resting CD4 T cells
Given that HIV-mediated actin dynamics play an im-
portant role in HIV infection of resting CD4 T cells
[12,14,19], we speculated that genistein-mediated inhib-
ition of HIV infection may be related to its inhibition of
actin activity. The direct effect of genistein on T cell
actin dynamics has not been studied although genistein
inhibits SDF-1-mediated chemotaxis of memory CD4 T
cells (Figure 1A to D) [45]. Genistein has been suggested
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Figure 2 Genistein inhibits HIV infection of resting CD4 T cells and macrophages. (A) Genistein inhibits HIV infection of resting CD4 T cells
in additional three donors. Experimental procedures are described in Figure 1E. (B) Dosage-dependent inhibition of HIV infection of resting CD4 T
cells. Resting CD4 T cells from two additional donors were pretreated with genistein at different dosages for 1 hour, and then infected with HIV-1
NL4-3 for 2 hours at 37°C in the continuous presence of these inhibitors. Following infection, cells were washed twice and a single dose of
genistein was added to the culture. Cells were culture for 5 days and activated at day 5 with anti-CD3/CD28 magnetic beads (4 beads per cell).
Viral replication was measured by p24 release. (C) Genistein inhibits HIV infection of primary macrophages. Human peripheral blood monocyte-
derived macrophages were pretreated with genistein or DMSO (1%, control) for 1 hour, and then infected with HIV (THRO.c/2626) for 2 hours.
Following infection, cells were washed to remove HIV and the inhibitor, and then continuously cultured in the absence of genistein to monitor
viral replication. (D) Sunitinib inhibits HIV infection of resting CD4 T cells. Cells from two donors were pretreated with different dosages of
sunitinib for 1 hour, and then infected with HIV-1NL4-3 for 2 hours in the continuous presence of the inhibitor. Following infection, cells were
washed twice and then cultured in the absence of the inhibitor for 5 days. Cells were activated at day 5 with anti-CD3/CD28 magnetic beads,
and viral replication was measured by p24 release. (E) AG1478 does not inhibit HIV infection of resting CD4 T cells. Resting CD4 T cells were
similarly pretreated with AG1478, and infected with HIV-1, as described in (D).
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such as formin-2 and profilin [46]. Thus, we measured ef-
fects of genistein on SDF-1-mediated actin dynamics in
resting memory CD4 T cells which were pre-treated with
3.7 μM genistein for 1 hour. This dosage of genisteinslightly increased basal levels of actin density in some do-
nors but not the others (data not shown). Following genis-
tein pre-treatment, cells were treated with SDF-1 for a
time course and actin dynamics were measured. As shown

































































































































































































Figure 3 Genistein inhibits HIV DNA synthesis and viral DNA
nuclear localization. (A) Genistein does not inhibit viral entry into
resting CD4 T cells. Resting CD4 T cells from two donors were
pretreated with genistein for 1 hour, and then infected with Nef-
luciferase tagged HIV-1 for 2 hours. Cells were washed and luciferase
activity was measured in live cells. (B) Genistein inhibits viral DNA
synthesis in CD4 T cells. Resting memory CD4 T cells were pretreated
with genistein (10 μM) or DMSO (1%, control) for 1 hour, and then
infected with HIV-1NL4-3 for 2 hour in the presence of genistein. Cells
were washed twice to remove HIV and genistein, cultured for 5 days,
and then activated at day 5 with anti-CD3/CD28 magnetic beads.
Infected cells were harvested and lysed at different time points
following infection to extract total cellular DNA. HIV DNA was
measured by using real time PCR using equal amount of total DNA.
(C and D) Resting memory CD4 T cells were similarly pretreated with
genistein (10 μM) and infected with HIV. Viral DNA was measured at
2 and 4 hours post infection. Infected cells were also used for
fractionation and purification of nuclear DNA. HIV nuclear DNA was
measured using real time PCR using equal amount of total DNA (D).
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actin depolymerization at later times (after 5 min), which
reduced the sustainability of actin polymerization, decreas-
ing the overall actin dynamics. Similar results were ob-
served in another donor (Additional file 1: Figure S3).
Confocal microscopy of genistein-treated cells revealed
that there was no gross alteration of cell morphology by
genistein, but at 60 minutes after SDF-1 treatment, genis-
tein also appeared to increase nuclear actin accumulation
in this particular donor (Figure 4B and Additional file
1: Figure S4).
To determine whether genistein similarly affects HIV-
mediated actin dynamics, we pre-treated resting memory
CD4 T cells with genistein, infected cells with HIV-1,
and then measured virus-mediated actin dynamics. As
shown in Figure 5A and B, we observed a similar pattern
as seen in Figure 4A. Again, genistein did not inhibit
HIV-mediated early actin polymerization (0.5-1 minute),
but promoted faster actin depolymerization, reducing
the overall actin activity (Additional file 1: Figure S5).
We also performed Western blots to examine effects of
genistein on actin regulators such as the LIM domain
kinase (LIMK) and cofilin [12,14], which mediate actin
depolymerization [61]. As shown in Figure 5C, we ob-
served that genistein decreased HIV-1-mediated LIMK
and cofilin phosphorylation and activation, disrupting the
signaling pathway. Nevertheless, the effect is likely indir-
ect, possibly resulting from inhibition of upstream tyrosine
kinases, as LIMK1/2 and cofilin are phosphorylated on
threonine 508/505 and serine 3, respectively [62,63].
Pre-stimulation of CD4/CXCR4 receptors diminishes
genistein-mediated inhibition of HIV infection of resting
CD4 T cells
Genistein is a general tyrosine kinase inhibitor, and it
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Figure 4 Genistein interferes with SDF-1-mediated actin dynamics in resting memory CD4 T cells. (A) Resting memory CD4 T cells from
two donors were pretreated with genistein (3.7 μM) or mock-treated for 1 hour at 37°C, and then stimulated with SDF-1 (12.5 nM) for various
times, from 0.5 minute to 60 minutes. Cells were fixed, stained with FITC-phalloidin for F-actin, and then analyzed with flow cytometer. (B)
Confocal images of cells stained in (A), showing F-actin staining. Images were acquired and analyzed at identical conditions for all samples. Some
cells were also stained with DAPI (4′, 6-diamidino-2-phenylindole) for nuclear DNA.
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Figure 5 Genistein interferes with HIV-mediated actin dynamics in resting memory CD4 T cells. (A) Resting memory CD4 T cells from two
donors were pretreated with genistein (3.7 μM) or mock-treated for 1 hour at 37°C, and then stimulated with HIV-1NL4-3 (100 ng) for various
times. Cells were fixed, stained with FITC-phalloidin for F-actin, and then analyzed with a flow cytometer. (B) Confocal images of cells stained in
(A), showing F-actin staining. Images were acquired and analyzed at identical conditions for all samples. (C) Resting memory CD4 T cells were
pretreated with 10 μM genistein for 1 hour, and then treated with HIV-1NL4-3 for a time course. Cells were then analyzed by Western blot for LIMK
and cofilin activation, using an anti-phospho-LIMK antibody or an anti-cofilin antibody. The same blots were also probed with an anti-human
GAPDH antibody for loading control and normalization.
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tyrosine kinases that are involved in actin dynamics.
Previously, we have demonstrated that pre-stimulation
of resting CD4 T cells with anti-CD4/CXCR4 beads
triggers cell signaling and actin reorganization that en-
hances HIV-1 infection of resting T cells [12]. This
low-level stimulation (two beads per cell) does not
block HIV entry or activate T cells, but greatly pro-
motes actin dynamics that eliminate the inhibitory ef-
fect of the actin modulator jasplakinolide (at 120 and
600 nM) on HIV infection of resting T cells [12]. We
speculated that similar stimulation of actin dynamics
in resting CD4 T cells with anti-CD4/CXCR4 beads
may also overcome genistein inhibition of HIV infec-
tion. As expected, we observed a complete loss of the
inhibition by genistein when cells were pre-stimulated
with anti-CD4/CXCR4 beads (Figure 6A to D), whereas in
unstimulated cells, genistein inhibited over 99% of viral
replication in CD4 T cells of the same donor (at day 8)
(Figure 6C and D). Similar results were observed in an-
other donor, although this donor demonstrated less inhib-
ition of HIV-1 by 10 μM genistein (Figure 6E and F).
These results are consistent with our hypothesis that ge-
nistein inhibits HIV infection through interference of the
CD4/CXCR4-mediated receptor signaling that leads to
actin dynamics.
Genistein safety evaluation in rhesus macaques
Genistein is naturally made in a number of plants, such as
soybeans, and its consumption is associated with a lower
incidence of metastatic prostate cancer in southeast Asians
who subsist on a soybean-based diet [41,64-67]. The aver-
age steady-state blood levels of genistein in Japanese men,
who subsist on a soy-based diet, were 0.28 μM [66]. In a
phase I human clinical trial, subjects were given genistein
(43-90% pure) at 2–8 mg/kg orally, and no significant cyto-
toxicities were observed among these cancer patients [42].
The subjects sustained a maximal total plasma genistein
concentration between 4.3 to 16.3 μM, with a drug half-life
of 15 to 22 hours [42]. Based on this phase I study, we also
initiated a preliminary animal trial to evaluate the safety of
daily administration of genistein. Three rhesus macaques
of Chinese-origin (Macaca mulatta) were chronically
infected with SIVmac251 with plasma viral loads between
102 to 104 copies/ml. Each animal was given a monother-
apy of genistein at 10 mg/kg orally for 12 weeks. We did
not observe adverse effects on any of these animals, and
their CD4 T cell counts and percentages remained stable
in these 12 weeks (Figure 7A and B). We also performed a
one-time measurement of plasma viral load at the end of
the 12 weeks. Two of the animals (PO15 and HG40) had a
reduction of viral load to undetectable level, whereas the
third animal (IV30) had no reduction (Figure 7C). Given
the donor variations and dosage-independent inhibition ofHIV observed in our in vitro CD4 T cell cultures, IV30
may need longer treatment or a different genistein dosage.
However, we do not excluded that drug resistance might
also develop, although it is expected to be more difficult
for cellular targets. Further studies are certainly needed
to address the in vivo efficacy of genistein, and to define
optimal dosages for maximal viral inhibition in individ-
ual animals.
Discussion
In this report, we demonstrated that the T cell chemo-
taxis inhibitor, genistein, interfered with SDF-1-mediated
actin dynamics. Similar treatment of resting T cells with
genistein also interfered with HIV-1-mediated actin ac-
tivity and inhibited HIV infection of resting T cells. Ge-
nistein is a tyrosine kinase inhibitor found in a number
of plants such as soybeans and flemingia vestita [38],
and is being tested for treatment of cancers such as
leukemia [39,40] and prostate cancer [41,42]. Dietary ge-
nistein has also been shown to inhibit metastasis of hu-
man prostate cancer in mice [41,42]. Genistein inhibits
human prostate cancer cell motility through inhibiting
pro-motility signaling, specifically, by inhibiting the acti-
vation of FAK and the p38 MAPK-HSP27 pathway
[43,44]. Genistein has also been suggested to modulate
the cellular distribution of actin-binding proteins in hu-
man stromal cells by inducing the peri-nuclear accumu-
lation of the actin-binding protein formin-2 and profilin
[46]. Although the exact signaling molecules targeted by
genistein in HIV infection were not systematically inves-
tigated in our study, genistein was found to inhibit the
overall phosphorylation of LIMK and cofilin (Figure 5C),
two of the main actin regulators involved in T cell mo-
bility and HIV infection [12,14]. In cells, multiple actin
regulatory proteins, such as gelsolin [68,69], villin [70],
ezrin [71], cortactin [72-74], Rac1 [75], and WASP [76],
require tyrosine phosphorylation for activity. Certainly,
some of these molecules such as ezrin [23,24], Rac1
[14,77], and WASP [25,26] have also been implicated in
HIV infection of CD4 T cells. It is possible that genistein
may additionally affect these actin regulators leading to the
inhibition of HIV-1 replication in resting CD4 T cells.
Our results on genistein-mediated reduction of both
actin activity and HIV infection are consistent with a
demonstrated role of early actin dynamics in HIV infec-
tion of resting T cells [12,14,17,19,51]. Our findings are
also consistent with previous studies showing that
chemokines such as CCL2, CCL19 augment gp120-
induced actin dynamics in resting CD4 T cells, which
greatly facilitate HIV DNA synthesis and nuclear migra-
tion in resting T cells [17,19]. In addition, our results are
aligned with a recent study demonstrating that the
N-terminal fragment of the Slit2 protein inhibits X4


































































































































Figure 6 Anti-CD4/CXCR4 bead pre-stimulation abolishes genistein inhibition of HIV infection of resting CD4 T cells. (A and B) Purified
resting CD4 T cells were cultured in medium overnight (A) or pre-stimulated with anti-CD4/CXCR4 magnetic beads (2 beads per cell) overnight
(B), and then treated with genistein (10 μM) for 1 hour. Cells were infected with HIV-1NL4-3 for 2 hours, washed, incubated for 5 days in the absence of
genistein, and then activated by anti-CD3/CD28 magnetic beads (2 beads per cell). Viral replication was measured by p24 release into the supernatant.
(C) Viral replication measured at day 8 post infection. (D) The full viral replication course in cells pre-stimulated with anti-CD4/CXCR4 beads. (E and F) A
repeat of the experiment in another donor. Viral replication at day 10 and 11 is shown.
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Rac1-LIMK-cofilin pathway for actin rearrangement
[78]. Similar interference of the HIV-mediated actin
pathway has also been reported in cannabinoid recep-
tor 2-mediated inhibition of X4 viral infection of pri-
mary blood CD4 T cells [79]. Nevertheless, genisteincan inhibit multiple cellular kinases, and we did not ex-
clude that the inhibition of HIV replication by genistein is
a combined effect with the inhibition of actin signaling.
HIV infection is a chronic disease that requires life-
long treatment on a daily basis. Thus, persistent and dir-
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Figure 7 Genistein monotherapy on Chinese rhesus macaques
with chronic SIV infectionc. (A and B) Three Chinese rhesus
macaques were chronically infected with SIVmac251. Each animal
received 10 mg/kg of genistein orally for 12 weeks. The dynamics of
the absolute CD4+ T cell count (A) and the percentages of CD4+ T
cells (B) in peripheral blood were monitored. The percentage of CD4+
T cells were calculated by gating on total CD3+ T lymphocytes
analyzed by flow cytometry. The absolute CD4+ T cell counts were
generated from the calculation of percentages of CD4+ T cells, CD3+ T
cells and lymphocytes from the complete blood count (CBC).
(C) Plasma viral load before and after genistein monotherapy
was also measured.
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mediated interference or diversion of HIV-dependent sig-
nal transduction to actin activity is achievable. It is our
interest to search for inhibitors that are capable of interfer-
ing with virus-mediated actin activity while minimally af-
fecting cellular actin dynamics. It is possible that such
inhibitors may not drastically diminish HIV replication in ashort-term. However, with long-term treatment and pos-
sibly lower viral drug-resistance, persistent depression of
viral loads could be achievable. Genistein has the potential
to be one of these cellular protein-based anti-HIV drugs
with a favorably low cytotoxicity.
Conclusions
In conclusion, in our study, we demonstrated that genis-
tein inhibits HIV infection of CD4 T cells and macro-
phages. These results may suggest that similar naturally-
occurring kinase inhibitors, with little or no-detectable
cytotoxicity, may be good candidates for long-term man-
agement of HIV infection. Such cellular protein-based
therapy may also have additional advantages in combat-
ing HIV drug-resistance.
Methods
Isolation of resting CD4 T cells and memory CD4 T cells
from peripheral blood
Resting CD4 T cells were purified from peripheral blood
by two rounds of negative selection as previously de-
scribed [52]. All protocols involving human subjects
were reviewed and approved by the George Mason Uni-
versity IRB. Briefly, for the first round of depletion, we
used monoclonal antibodies against human CD14, CD56
and HLA-DR, DP, DQ (BD biosciences). For the second
round of depletion, we used monoclonal antibodies
against human CD8, CD11b and CD19 (BD biosciences).
To purify resting memory CD4 T cells, we used antibodies
against human CD8, CD11b, CD19 and CD45RA (BD bio-
sciences) for the second round depletion. Antibody bound
cells were depleted by using Dynabeads Pan Mouse IgG
(Invitrogen). Purified cells were cultured in RPMI-1640
medium supplemented with 10% heat-inactivated fetal bo-
vine serum (Invitrogen), penicillin (50 U/ml) (Invitrogen),
and streptomycin (50 μg/ml) (Invitrogen). Cells were rested
overnight before infection or treatment.
Differentiation of macrophages from peripheral blood
monocytes
Macrophages were differentiated from human monocytes
from the peripheral blood of HIV-1 negative donors as
previously described [80]. Briefly, two million peripheral
blood mononuclear cells were plated into each well of six-
well plates in serum free RPMI medium for one hour. Ad-
herent cells were cultured in RPMI plus 10% heat
inactivated fetal bovine serum (FBS) with 10 ng/ml macro-
phage colony stimulating factor (M-CSF) (R&D System)
for two weeks with medium change for every two days.
Virus preparation and infection of T cells and
macrophages
Virus stocks of HIV-1NL4-3 [81] and THRO.c/2626 [53]
were prepared by transfection of 293T cells with cloned
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harvested at 48 hours and filtered through a 0.45 μm
nitrocellulose membrane. Virus titer (TCID50) was mea-
sured by infection of a Rev-dependent indicator cell line,
Rev-CEM [82,83]. For infection of resting CD4 T cells,
103.5 to 104.5 TCID50 units of HIV-1 were used to infect
106 cells. For infection, CD4 T cells were pretreated with
genistein, herbimycin, 8-Br-cAMP, or 8-Br-cGMP, incu-
bated with the virus for 2 hours at 37°C, and then
washed twice with medium to remove unbound virus
and inhibitors. Infected cells were resuspended into fresh
RPMI-1640 medium supplemented with 10% heat-
inactivated fetal bovine serum, penicillin (50 U/ml), and
streptomycin (50 μg/ml) at a density of 106 per ml and
incubated for 5 days without stimulation. Cells were ac-
tivated at day 5 with anti-CD3/CD28 magnetic beads at
2 to 4 beads per cell. For the viral replication assay, 10%
of infected cells were taken at days 1, 3, 5, 6, 7, 8, and 9
post infection.
For HIV infection of macrophages, cells were pretreated
with genistein (10 μg/ml) or DMSO (1%) for 1 hour,
infected at 37°C for 2 hours. Infected cells were washed
three times and continuously cultured in RPMI plus 10%
FBS without M-CSF. Fresh medium was added every two
days. Viral replication was monitored by harvesting super-
natant. Levels of p24 in the supernatant were measured
using Perkin Elmer Alliance p24 antigen ELISA Kit
(Perkin Elmer). Plates were kinetically read using an
ELx808 automatic microplate reader (Bio-Tek Instru-
ments) at 630 nm.
SIV infection and genistein treatment of rhesus macaques
Three rhesus macaques of Chinese-origin (Macaca
mulatta) were used. All animals were housed at the
Tulane National Primate Research Center (TNPRC) and
maintained in accordance with the standards of the
American Association for Accreditation of Laboratory
Animal Care and the “Guide for the Care and Use of
Laboratory Animals” prepared by the National Re-
search Council. All studies were reviewed and ap-
proved by the Tulane Institutional Animal Care and
Use Committee (IACUC). All animals were in the
chronic phase of SIVmac251 infection with the plasma
viral loads in between 102 to 104 copies/ml. Each ani-
mal received 10 mg/kg of genistein daily for 12 weeks
by oral administration.
Quantification of plasma viral RNA in infected rhesus
macaques
Real-Time PCR was performed by the Pathogen Detec-
tion and Quantitation Core (PDQC) of Tulane National
Primate Research Center. Plasma samples were spiked
with armored RNA (aRNA; Asurgen, Austin, TX) and
centrifuged at 25,000 x g for 1 hour. Viral RNA (vRNA)was extracted from the pellet with Proteinase K (2.5 mg/ml;
Life Tech, Carlsbad, CA) and the High Pure Viral RNA kit
(Roche Indianapolis, IN). Eluted vRNA (100 μl) was then
subjected to the RNA Clean and Concentrator kit (ZYMO
Research, Irvine, CA) and eluted in 50 μl from which 15 μl
was reverse transcribed using MultiScribe™ Reverse Tran-
scriptase (Life Tech) in a 50-μL gene specific reaction. Four-
teen microliters of cDNA was added to TaqMan gene
expression master mix (Life Tech) along with primers and
probe targeting the gag region of SIVmac239 and subjected
to 40 cycles of qPCR analyses. Fluorescence signals were
detected with an Applied Biosystems 7900HT Se-
quence Detector. Data were captured and analyzed
with Sequence Detector Software (Life Tech). Viral
copy numbers were calculated by plotting CT values
obtained from samples against a standard curve generated
with in vitro-transcribed RNA representing known viral
copy numbers (and controlled by addition of known cop-
ies of aRNA). The limit of detection of the assay is 119
copies per ml of plasma.
Pre-treatment of cells with signaling pathway inhibitors
Unless specified, cells were pre-treated with pertussis toxin
(Sigma) (100 ng/ml), genistein (Calbiochem) (1 μg/ml or
3.7 μM) or herbimycin (Sigma) (1 μM) for 1 hour at 37°C,
or with 8-Br-cAMP or 8-Br-cGMP (Sigma) (100 μM) for
15 minutes at room temperature, and then infected
with HIV.
Chemotaxis assay
For chemo-attractant assay, one half million resting CD4
T cells were suspended into 100 μl of RPMI-1640
medium, and then added to the upper chamber of a
transwell plate (6.5 mm diameter and 5 μm pore size
with a polycarbonate membrane) (Corning). The lower
chamber was filled with 600 μl of medium premixed
with SDF-1 (R&D systems). The transwell plate was in-
cubated at 37°C for 2 hours, and then the upper cham-
ber was removed and cells in the lower chamber were
counted in a Beckman coulter Z2 cell and particle
counter.
FITC-Phalloidin staining of F-actin and flow cytometry
One million cells pretreated with genistein (3.7 μM) for
1 hour at 37°C were stimulated with SDF-1 or HIV-1 for
various periods of time. Cells were incubated at 37°C in
an Eppendorf Thermomixer with gentle agitation (600
rpm) to prevent cells settling at the bottom. F-actin
staining using FITC-labeled phalloidin (Sigma) was car-
ried out according to the manufacturer’s recommenda-
tion with minor modifications. Briefly, cells were
pelleted, fixed and permeabilized with CytoPerm/Cytofix
buffer (BD Biosciences) for 20 minutes at room
temperature, washed with cold Perm/Wash buffer (BD
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mM FITC-labeled phalloidin (Sigma) for 30 minutes on
ice in the dark. After washing twice with cold Perm/Wash
buffer, cells were resuspended in 1% paraformaldehyde
and analyzed on a FACSCalibur (BD Biosciences).
Nuclear DNA fractionation and real time PCR
measurement of HIV DNA
Infected cells were directly lysed in DNA extraction lysis
buffer (SV Genomic DNA Isolation System, Promega).
Total cellular DNA was extracted and viral total DNA
was measured by real time PCR as previously described
[12]. The fractionation of viral DNA in memory T cells
was conducted as previously described [12]. Briefly, cells
were pelleted at 270 x g for 5 minutes in a microfuge at
4°C, washed once with ice-cold PBS, resuspended into
ice-cold cell lysis buffer (10 mM Tris-Cl, pH 7.5, 140
mM NaCl, 5 mM KCl, 1% EDTA, 1% NP-40), incubated
on ice for 5 to 10 minutes, and then centrifuged at 270 x g
for 5 minutes at 4°C to pellet the nuclei. The nuclear pellet
was washed once with ice-cold cell lysis buffer and then
dissolved in DNA extraction lysis buffer (SV Total RNA
Isolation System, Promega). Total cellular DNA was
extracted and viral DNA was measured by real time PCR
as previously described [12].
HIV entry assay
The Nef-luciferase-based HIV entry assay was performed
as described [56]. Briefly, cells (1 × 106) were infected with
200 ng of Nef-luciferase containing viruses at 37°C for 2
hours, and then washed three times with medium. Cells
were resuspended in 0.1 ml of luciferase assay buffer
(Promega) and luciferase activity was measured in live
cells using a GloMax-Multi Detection System (Promega).
Western blot to detect LIMK and cofilin activation
One million cells were lysed in NuPAGE LDS Sample Buf-
fer (Invitrogen) and separated by SDS-PAGE, and then
transferred onto nitrocellulose membranes (Invitrogen).
The blots were washed, blocked with Starting Block
blocking buffer (Pierce), and incubated overnight with
rabbit polyclonal antibodies specific for phospho-LIMK1
/2 (1:1000 dilution) or phospho-cofilin (ser3) (1:500 dilu-
tion) (Cell Signaling). The blots were washed and then in-
cubated with goat anti-rabbit 800cw labeled antibodies
(Li-cor Biosciences) (1:5000 diluted) for 1h at 4°C. The
blots were washed three times and scanned with Odyssey
Infrared Imager (Li-cor Biosciences). The same blots were
also probed with goat anti-GAPDH antibodies (Abcam,
ab9483) (1:1000 dilution). The secondary antibody
staining was performed using 1:5000 dilution of Rabbit
Anti-Goat IgG DyLight 680 antibodies (KPL). The
blots were imaged on an ODYSSEY Infrared imager
(Li-Cor Biosciences).Conjugation of antibodies to magnetic beads and
stimulation of resting CD4 T cells
Monoclonal antibodies against Human CD3 (clone
UCHT1), CD28 (clone CD28.2), CD4 (clone PRA-T4) or
CXCR4 (clone 12G5) were from BD Biosciences. Anti-
bodies were conjugated to magnetic beads and used to
stimulate resting CD4 T cells as previously described [12].
Confocal Microscopy
Stained cells were imaged using a Zeiss Laser Scanning
Microscope, LSM 510 META, with a 40 NA 1.3 or 60
NA 1.4 oil DIC Plan-Neofluar objective. Samples were
excited with a laser line, 488 nm for FITC. Images were
simultaneously recorded in two channels: channel one,
fluorescent emissions from 505 to 530 nm for FITC
(green); channel two, DIC. Images were processed and
analyzed by the LSM 510 META software.
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